Arthrex prevails in patent dispute over wrist fracture device
In a win for medical device maker Arthrex, a federal judge in Delaware has ruled that its wrist-plating system does not infringe a patent owned by competitor TriMed Technologies.
Lundbeck loses €150m pay-for-delay appeal
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
WHO urges vigilance against fake COVID-19 vaccines
The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.
Fed Circ. affirms Stanford genetics patent rejection
The Federal Circuit has affirmed a Patent Trial and Appeal Board decision denying Stanford University a patent application for calculating parent genes.
Supreme Court denies MS treatment patent petition
The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.
Abbott unit prevails in dispute over catheter patent
In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.
Snyders revives patent claims against St Jude Medical
Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.
Wilson Sonsini adds Boston deals expert from Ropes & Gray
Wilson Sonsini & Rosati has hired Mark Bellomy as a partner for the firm’s technology transaction practice in Boston.
Pyxis secures ADC licence from Pfizer
Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Reviewing the inter partes review
The establishment of the US Patent Trial and Appeal Board in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.
